Cargando…

Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer

It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Miki, Yuichiro, Yashiro, Masakazu, Kuroda, Kenji, Okuno, Tomohisa, Togano, Shingo, Masuda, Go, Kasashima, Hiroaki, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877362/
https://www.ncbi.nlm.nih.gov/pubmed/33381922
http://dx.doi.org/10.1002/cam4.3616
_version_ 1783650151812825088
author Miki, Yuichiro
Yashiro, Masakazu
Kuroda, Kenji
Okuno, Tomohisa
Togano, Shingo
Masuda, Go
Kasashima, Hiroaki
Ohira, Masaichi
author_facet Miki, Yuichiro
Yashiro, Masakazu
Kuroda, Kenji
Okuno, Tomohisa
Togano, Shingo
Masuda, Go
Kasashima, Hiroaki
Ohira, Masaichi
author_sort Miki, Yuichiro
collection PubMed
description It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigated as detecting tools for CTCs. Thus, this study aims to clarify the significance of carcinoembryonic antigen (CEA, CD66e)‐positive CTCs in patients with gastric cancer. A total of 150 patients with gastric cancer were enrolled in this study. The mononuclear fraction of peripheral blood was enriched by Ficoll. The number of cells was enumerated depending on the positivity of EpCAM and CEA or CK by flow cytometry. The association of these cells with clinicopathologic characteristics was investigated. The mean age was 70 (range 28–92). The macroscopic type of gastric cancer was classified as 0/1/2/3/4/5 in 59/11/22/38/16/4 patients, respectively. Seventy‐one patients (47.3%) were diagnosed with intestinal‐type cancer, while 76 patients (50.7%) were diagnosed with the diffuse type. The mean numbers of cells with EpCAM−CK+, EpCAM+CK−, EpCAM+CK+, EpCAM−CEA+, EpCAM+CEA−, and EpCAM+CEA+ were 618, 237, 19.9, 1147, 291, and 7.41, respectively. The number of EpCAM−CEA+cells was significantly higher in patients with stage II–III and IV than in patients with stage I. The 3‐year RFS rate in patients with a high number of EpCAM−CEA+cells (>=622) was 57.5%, while it was 79.3% in patients with a low number of EpCAM−CEA+cells (<622) (log‐rank p = 0.0079). Thus, we conclude that CEA‐positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer.
format Online
Article
Text
id pubmed-7877362
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78773622021-02-18 Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer Miki, Yuichiro Yashiro, Masakazu Kuroda, Kenji Okuno, Tomohisa Togano, Shingo Masuda, Go Kasashima, Hiroaki Ohira, Masaichi Cancer Med Clinical Cancer Research It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigated as detecting tools for CTCs. Thus, this study aims to clarify the significance of carcinoembryonic antigen (CEA, CD66e)‐positive CTCs in patients with gastric cancer. A total of 150 patients with gastric cancer were enrolled in this study. The mononuclear fraction of peripheral blood was enriched by Ficoll. The number of cells was enumerated depending on the positivity of EpCAM and CEA or CK by flow cytometry. The association of these cells with clinicopathologic characteristics was investigated. The mean age was 70 (range 28–92). The macroscopic type of gastric cancer was classified as 0/1/2/3/4/5 in 59/11/22/38/16/4 patients, respectively. Seventy‐one patients (47.3%) were diagnosed with intestinal‐type cancer, while 76 patients (50.7%) were diagnosed with the diffuse type. The mean numbers of cells with EpCAM−CK+, EpCAM+CK−, EpCAM+CK+, EpCAM−CEA+, EpCAM+CEA−, and EpCAM+CEA+ were 618, 237, 19.9, 1147, 291, and 7.41, respectively. The number of EpCAM−CEA+cells was significantly higher in patients with stage II–III and IV than in patients with stage I. The 3‐year RFS rate in patients with a high number of EpCAM−CEA+cells (>=622) was 57.5%, while it was 79.3% in patients with a low number of EpCAM−CEA+cells (<622) (log‐rank p = 0.0079). Thus, we conclude that CEA‐positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer. John Wiley and Sons Inc. 2020-12-31 /pmc/articles/PMC7877362/ /pubmed/33381922 http://dx.doi.org/10.1002/cam4.3616 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Miki, Yuichiro
Yashiro, Masakazu
Kuroda, Kenji
Okuno, Tomohisa
Togano, Shingo
Masuda, Go
Kasashima, Hiroaki
Ohira, Masaichi
Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title_full Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title_fullStr Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title_full_unstemmed Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title_short Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
title_sort circulating cea‐positive and epcam‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877362/
https://www.ncbi.nlm.nih.gov/pubmed/33381922
http://dx.doi.org/10.1002/cam4.3616
work_keys_str_mv AT mikiyuichiro circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT yashiromasakazu circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT kurodakenji circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT okunotomohisa circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT toganoshingo circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT masudago circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT kasashimahiroaki circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer
AT ohiramasaichi circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer